Anika Therapeutics CEO Dr. Cheryl Blanchard to Present at 43rd Annual J.P. Morgan Healthcare Conference
Anika Therapeutics CEO Dr. Cheryl Blanchard to Present at 43rd Annual J.P. Morgan Healthcare Conference
The presentation will be webcast live on the Events and Webcasts page on Anika Therapeutics' website.Anika Therapeutics' CEO will present at the J.P. Morgan Healthcare Conference on January 16, 2025, and meet investors.
阿尼卡療法的首席執行官將在2025年1月16日的摩根大通醫療會議上進行演講，並與投資者會面。
Quiver AI Summary
Quiver AI 概要
Anika Therapeutics, Inc. has announced that Dr. Cheryl Blanchard, the company's President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on January 16, 2025, at 9:45 am PT. The presentation will be available for live streaming and will also be archived for 30 days on the company's website. Additionally, Anika's management will hold one-on-one investor meetings during the event. Anika Therapeutics is focused on joint preservation in early intervention orthopedics, specializing in products that utilize hyaluronic acid and implant solutions to enhance orthopedic care, particularly in managing osteoarthritis pain and regenerative solutions. The company is headquartered near Boston, Massachusetts.
阿尼卡療法公司宣佈，公司的總裁兼首席執行官Cheryl Blanchard博士將在2025年1月16日上午9:45（太平洋時間）於舊金山舉行的第43屆年度摩根大通醫療會議上進行演講。該演講將可通過直播觀看，並將在公司網站上存檔30天。此外，阿尼卡的管理層將在活動期間舉行一對一的投資者會議。阿尼卡療法專注於早期干預骨科中的關節保護，專門開發利用透明質酸和植入解決方案的產品，以增強骨科護理，特別是在管理骨關節炎疼痛和再生解決方案方面。該公司總部位於馬薩諸塞州波士頓附近。
Potential Positives
潛在的積極因素
- Participation in the prestigious 43rd Annual J.P. Morgan Healthcare Conference highlights Anika Therapeutics' credibility and position within the healthcare sector.
- Live webcast of the presentation increases visibility and access for investors and stakeholders, showcasing the company's commitment to transparency.
- One-on-one investor meetings provide an opportunity for direct engagement with management, potentially strengthening investor relations and interest in the company.
- 參與這一享有聲望的第43屆年度摩根大通醫療會議突顯了阿尼卡療法在醫療領域的信譽和地位。
- 演講的直播提高了投資者和利益相關者的可見性和訪問權限，展示了公司對透明度的承諾。
- 一對一的投資者會議提供了與管理層直接接觸的機會，有助於增強投資者關係和對公司的興趣。
Potential Negatives
潛在負面因素
- None
- 無
FAQ
常見問題
When is Anika Therapeutics presenting at the J.P. Morgan Healthcare Conference?
阿尼卡療法將於何時在摩根士丹利醫療會議上發表演講？
Anika Therapeutics will present on January 16, 2025, at 9:45 am PT / 12:45 pm ET.
阿尼卡療法將於2025年1月16日上午9:45（太平洋時間）/ 下午12:45（東部時間）進行演講。
Where can I watch the Anika Therapeutics presentation?
我在哪裏可以觀看阿尼卡療法的演講？
The presentation will be webcast live on the Events and Webcasts page on Anika Therapeutics' website.
此次演講將在阿尼卡療法官方網站的活動與直播頁面進行直播。
Who is Dr. Cheryl Blanchard?
謝麗爾·布蘭查德博士是誰？
Dr. Cheryl Blanchard is the President and CEO of Anika Therapeutics.
謝麗爾·布蘭查德博士是阿尼卡療法的總裁兼首席執行官。
How can I schedule a meeting with Anika's management?
我如何才能安排與阿尼卡療法管理層的會議？
To schedule a meeting, contact Anika's Investor Relations at investorrelations@anika.com.
要安排會議，請聯繫阿尼卡療法的投資者關係部門，郵箱是 investorrelations@anika.com。
What does Anika Therapeutics focus on?
阿尼卡療法專注於什麼？
Anika Therapeutics focuses on joint preservation and early intervention in orthopedic care, including Osteoarthritis Pain Management.
阿尼卡療法專注於關節保護和骨科護理的早期干預，包括骨關節炎疼痛管理。
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
免責聲明：這是由GlobeNewswire分發的新聞稿的人工智能生成摘要。用於總結這份稿件的模型可能會出錯。請在這裏查看完整發佈。
$ANIK Hedge Fund Activity
$ANIk 對沖基金活動
We have seen 47 institutional investors add shares of $ANIK stock to their portfolio, and 68 decrease their positions in their most recent quarter.
我們看到47家機構投資者在最近一個季度中增加了對$ANIk股票的持有，68家機構減少了他們的頭寸。
Here are some of the largest recent moves:
以下是最近的一些重大變動：
- BLACKROCK, INC. added 157,707 shares (+9.8%) to their portfolio in Q3 2024
- RIVERWATER PARTNERS LLC added 86,037 shares (+539.1%) to their portfolio in Q3 2024
- AQR CAPITAL MANAGEMENT LLC removed 76,681 shares (-71.4%) from their portfolio in Q3 2024
- NUVEEN ASSET MANAGEMENT, LLC removed 58,761 shares (-58.7%) from their portfolio in Q3 2024
- MORGAN STANLEY removed 49,011 shares (-9.8%) from their portfolio in Q3 2024
- CITADEL ADVISORS LLC removed 47,063 shares (-52.8%) from their portfolio in Q3 2024
- VIRTUS INVESTMENT ADVISERS, INC. removed 45,579 shares (-100.0%) from their portfolio in Q3 2024
- 貝萊德公司在2024年第三季度增加了157,707股 (+9.8%) 到他們的投資組合中
- RIVERWATER PARTNERS LLC在2024年第三季度增加了86,037股 (+539.1%) 到他們的投資組合中
- AQR資本管理公司在2024年第三季度從他們的投資組合中移除了76,681股 (-71.4%)
- NUVEEN資產管理公司在2024年第三季度從他們的投資組合中移除了58,761股 (-58.7%)
- 摩根士丹利在2024年第三季度從他們的投資組合中移除了49,011股 (-9.8%)
- CITADEL顧問公司在2024年第三季度從他們的投資組合中移除了47,063股 (-52.8%)
- 維德思投資顧問公司在2024年第三季度從他們的投資組合中移除了45,579股 (-100.0%)
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
要跟蹤對沖基金的股票投資組合，請查看Quiver Quantitative的機構持有情況儀表。
Full Release
完整發佈
BEDFORD, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) --
Anika Therapeutics, Inc.
(NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and CEO of Anika, will present at the 43
rd
Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16, 2025 at 9:45am PT / 12:45pm ET. Management will also participate in one-on-one investor meetings throughout the event.
馬薩諸塞州貝德福德，2024年12月23日（全球新聞網） --
阿尼卡療法公司
（納斯達克：ANIK），一家專注於早期干預骨科的全球關節保護公司，今天宣佈阿尼卡的董事長兼首席執行官雪莉·布蘭查德博士將在第43屆
rd
雅培摩根醫療保健大會上發言，會議將於2025年1月16日星期四上午9:45（太平洋時間） / 下午12:45（東部時間）在舊金山舉行。管理層還將在整個活動期間參與一對一的投資者會議。
The presentation will be webcast live on the
Events and Webcasts page
under the Investors section of Anika Therapeutics' website and will be archived for 30 days following the presentation. For more information about this event or to schedule a one-on-one meeting with Anika's senior management, please contact Anika's Investor Relations at
investorrelations@anika.com
.
此次演講將通過
活動和網絡直播頁面現場直播
在阿尼卡療法官網的投資者專區，將在展示後保存30天。有關於該活動的更多信息或想安排與阿尼卡高級管理層的一對一會議，請聯繫阿尼卡的投資者關係部門，
investorrelations@anika.com
.
About Anika
Anika Therapeutics, Inc.
(NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people around the world. Our focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management and Regenerative Solutions, and our products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika's global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit
.
關於阿尼卡
阿尼卡療法公司
(納斯達克: ANIK)是一家全球關節保護公司，致力於創造並提供早期干預骨科護理的重大進展。我們利用在透明質酸和植入解決方案方面的核心專業知識，與臨牀醫生合作，提供微創產品，以恢復全球人們的積極生活。我們的重點是骨科領域內高機會的空間，包括骨關節炎疼痛管理和再生解決方案，我們的產品在關鍵護理場所（包括門診手術中心）高效交付。阿尼卡的全球業務總部位於馬薩諸塞州波士頓附近。有關阿尼卡的更多信息，請訪問
.
ANIKA, ANIKA THERAPEUTICS, CINGAL, HYALOFAST, INTEGRITY, MONOVISC, ORTHOVISC, TACTOSET, and the Anika logo are trademarks of Anika Therapeutics, Inc. or its subsidiaries or are licensed to Anika Therapeutics, Inc. for its use.
ANIKA、阿尼卡療法、CINGAL、HYALOFASt、INTEGRITY、MONOVISC、ORTHOVISC、TACTOSEt及阿尼卡標誌均爲阿尼卡療法公司或其子公司的商標，或已授權給阿尼卡療法公司使用。
For Investor Inquiries:
Anika Therapeutics, Inc.
Matt Hall, 781-457-9554
Director, Corporate Development and Investor Relations
investorrelations@anika.com
投資者諮詢：
阿尼卡療法公司
馬特·霍爾，781-457-9554
董事，企業發展和投資者關係
investorrelations@anika.com
